Online citations, reference lists, and bibliographies.
← Back to Search

Immunologic Abnormalities In Chronic Fatigue Syndrome

N. Klimas, F. Salvato, R. Morgan, M. Fletcher
Published 1990 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
The chronic fatigue syndrome (CFS), formerly known as chronic Epstein-Barr virus syndrome, is a clinical state of some complexity and uncertain etiology. In order to characterize in a comprehensive manner the status of laboratory markers associated with cellular immune function in patients with this syndrome, 30 patients with clinically defined CFS were studied. All of the subjects were found to have multiple abnormalities in these markers. The most consistent immunological abnormality detected among these patients, when compared with normal controls, was low natural killer (NK) cell cytotoxicity. The number of NK cells, as defined by reactivity with monoclonal antibody NKH.1 (CD56), was elevated, but the killing of K562 tumor cells per CD56 cell was significantly diminished. Lymphoproliferative responses after stimulation with phytohemagglutinin and pokeweed mitogen were decreased in most patients when compared with those in normal controls, as was the production of gamma interferon following mitogen stimulation. Lymphocyte phenotypic marker analysis of peripheral blood lymphocytes showed that there were significant differences between patients with CFS and controls. There was an increase in the percentage of suppressor-cytotoxic T lymphocytes, CD8, and a proportionally larger increase in the number of CD8 cells expressing the class II activation marker. Most patients had an elevated number of CD2 cells which expressed the activation marker CDw26. The numbers of CD4 cells and the helper subset of CD4+CD29+ cells in patients with CFS were not different from those in controls. There was, however, a significant decrease in the suppressor inducer subset of CD4+ CD45RA+ cells. The number of B cells, CD20 and CD21, were elevated, as were the numbers of a subset of B cells which coexpressed CD20 and CD5. The patterns of immune marker abnormalities observed was compatible with a chronic viral reactivation syndrome.
This paper references
10.2307/2332896
Nonparametric Statistics for the Behavioral Sciences.
F. David (1956)
10.1001/ARCHINTE.1961.03620090065008
Convalescence from influenza. A study of the psychological and clinical determinants.
J. Imboden (1961)
Epstein-Barr virus specific diagnostic tests in infectious mononucleosis.
W. Henle (1974)
10.1056/NEJM197411282912202
Depression of cell-mediated immunity during acute infectious mononucleosis.
R. Mangi (1974)
Spontaneous cytotoxicity of cultured human cell lines mediated by normal peripheral blood lymphocytes. III. Kinetic parameters.
D. Callewaert (1978)
10.1073/PNAS.76.8.4061
Separation of functional subsets of human T cells by a monoclonal antibody.
E. Reinherz (1979)
10.1016/0008-8749(79)90225-9
Spontaneous cytotoxicity of cultured human cell lines mediated by normal peripheral blood lymphocytes. II. Specificity for target antigens.
D. Callewaert (1979)
10.1002/9780470122747.CH1
Statistical analysis of enzyme kinetic data.
W. Cleland (1979)
The Epstein-Barr virus, p. 322-338
M. A. Epstein (1979)
Characterization of a human B lymphocyte-specific antigen.
P. Stashenko (1980)
A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2.
E. Reinherz (1980)
Characterization of a human B lymphocyte - specific anti
S. E. Strauss (1980)
Characterization of a human B lymphocyte-specific antigen
P. Stashenko (1980)
10.1016/0167-5699(81)90019-0
The characterization and function of human immunoregulatory T lymphocyte subsets.
E. Reinherz (1981)
10.1016/S0140-6736(81)90883-7
ASSAY OF AN INTERFERON-INDUCED ENZYME IN WHITE BLOOD CELLS AS A DIAGNOSTIC AID IN VIRAL DISEASES
A. Schattner (1981)
The characterization and function of human immunoregulatory T lymphocyte
E. L. Reinherz (1981)
Stress and immunologic competence in man, p. 229-257
J. Pamblad (1981)
10.1016/S0140-6736(82)90210-0
PROLONGED ATYPICAL ILLNESS ASSOCIATED WITH SEROLOGICAL EVIDENCE OF PERSISTENT EPSTEIN-BARR VIRUS INFECTION
M. Tobi (1982)
In vitro interactions of purified cloned human interferons on NK cells: enhanced activation.
S. Targan (1982)
10.1159/000287718
Vulnerability and Immune Response
L. Gottschalk (1983)
10.1126/SCIENCE.6685343
Homeostasis of the antibody response: immunoregulation by NK cells.
L. Abruzzo (1983)
Characterization of the gamma-interferon-mediated induction of antigen-presenting ability in P388D1 cells.
A. Zlotnik (1983)
10.1016/0008-8749(83)90374-X
Large granular lymphocytes inhibit the in vitro growth of autologous Epstein-Barr virus-infected B cells.
M. Masucci (1983)
10.1097/00007611-198411000-00007
Chronic Mononucleosis Syndrome
R. E. DuBois (1984)
10.1073/PNAS.81.8.2494
Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies.
K. Hayakawa (1984)
10.1001/ARCHPSYC.1984.01790160070008
Lymphocyte function in major depressive disorder.
S. Schleifer (1984)
Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody.
D. Fox (1984)
Antibodies to common leukocyte antigen p220 influence human T cell proliferation by modifying IL 2 receptor expression.
J. Ledbetter (1985)
10.7326/0003-4819-102-1
Evidence for active Epstein-Barr virus infection in patients with persistent, unexplained illnesses: elevated anti-early antigen antibodies.
J. Jones (1985)
10.7326/0003-4819-102-1-7
Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection.
S. Straus (1985)
10.1073/PNAS.82.21.7389
Selective loss of a subset of T helper cells in active multiple sclerosis.
L. M. Rose (1985)
The isolation and characterization of the human helper inducer T cell subset.
C. Morimoto (1985)
10.1056/NEJM198505303122201
In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.
D. Hafler (1985)
Characteristic T cell dysfunction in patients with chronic active Epstein-Barr virus infection (chronic infectious mononucleosis).
G. Tosato (1985)
Decreased natural cell-mediated cytotoxicity per effector cell in acquired immunodeficiency syndrome.
G. C. Baron (1985)
Kinetic models of natural cell cytotoxicity and their use for studying activated NK cells , p . 381 - 395
D. Callewaert (1985)
Kinetic models of natural cell cytotoxicity and their use for studying activated
D. M. Callewaert (1985)
Nonparametric one-way analysis of variance: a computational approach based on the Pillai-Bartlett trace
R. Zwick (1985)
10.1159/000234082
Immunological studies in patients with alcoholic liver disease: evidence for the in vivo activation of helper T cells and of the monocyte-macrophage system.
F. Spinozzi (1986)
10.1093/OXFORDJOURNALS.QJMED.A067944
Epstein Barr virus-specific immune defects in patients with persistent symptoms following infectious mononucleosis.
L. Borysiewicz (1986)
10.1002/ART.1780300802
Deficiency of the suppressor inducer subset of T lymphocytes in rheumatoid arthritis.
P. Emery (1987)
Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome.
M. Caligiuri (1987)
Use of whole blood methods in assessment of immune parameters in immunodeficiency states.
M. Fletcher (1987)
T cell regulatory disturbances in the rheumatic diseases.
S. Alpert (1987)
10.1001/JAMA.1987.03390170059028
Frequency of 'chronic active Epstein-Barr virus infection' in a general medical practice.
D. Buchwald (1987)
10.1002/ART.1780301212
Quantitative defect of CD4+2H4+ cells in systemic lupus erythematosus and Sjögren's syndrome.
K. Sato (1987)
10.1172/JCI112882
A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody.
C. Morimoto (1987)
10.1001/JAMA.1987.03390170053027
A cluster of patients with a chronic mononucleosis-like syndrome. Is Epstein-Barr virus the cause?
G. Holmes (1987)
Institute
SAS Researc (1987)
Remarkable depresJ. CLIN. MICROBIOL. IMMUNOLOGY OF CHRONIC FATIGUE 1409 sion of CD4+2H4+ T cells in severe chronic active Epstein-Barr virus infection
E. Franco (1987)
Remarkable depres J. CLIN. MICROBIOL. IMMUNOLOGY OF CHRONIC FATIGUE 1409 sion of CD4+2H4+ T cells in severe chronic active Epstein-Barr virus infection
E. Franco (1987)
10.1002/ANA.410240204
Fluctuations of CD4+ T‐cell subsets in remitting‐relapsing multiple sclerosis
L. Rose (1988)
10.1016/S0140-6736(88)92783-3
CLINICAL AND SEROLOGICAL FEATURES OF HUMAN HERPESVIRUS-6 INFECTION IN THREE ADULTS
J. Niederman (1988)
10.1001/JAMA.1988.03410070099036
Chronic fatigue syndrome and the diagnostic utility of antibody to Epstein-Barr virus early antigen.
W. Hellinger (1988)
10.7326/0003-4819-108-3-387
Chronic fatigue syndrome: a working case definition.
G. Holmes (1988)
10.1111/j.1600-065X.1988.tb00732.x
CD4+ T Cells: Specificity and Function
C. Janeway (1988)
Adenovirus type Il in a patient with lethal hemorrhagic colonic ulcers and chronic active Epstein-Barr virus infection
M. Okano (1988)
Immune dysfunction among chronic fatigue syndrome patients with clear evidence of Epstein-Barr virus reactivation
F. Salvato (1988)
10.1016/0090-1229(89)90191-8
Immunophenotyping in a multicenter study: the Transfusion Safety Study experience.
M. Fletcher (1989)
Psychiatric diagnoses in patients who have chronic fatigue syndrome.
M. Kruesi (1989)
10.1080/08870448908400373
A psychological assessment of chronic fatigue syndrome/chronic epstein-barr virus patients
Carrie Millon (1989)
Chronic Epstein-Barr virus infection.
E. Pallavicini (1992)



This paper is referenced by
10.3389/fmed.2021.628029
Hypothesis: Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Dominic Stanculescu (2021)
10.1101/2021.03.23.21254175
The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: analysis of high-throughput epigenetic and gene expression studies
J. Malato (2021)
10.1016/j.bbi.2021.03.023
Skewing of the B cell receptor repertoire in myalgic encephalomyelitis/chronic fatigue syndrome
W. Sato (2021)
10.1016/j.heliyon.2021.e07665
The SARS-CoV-2 receptor angiotensin-converting enzyme 2 (ACE2) in myalgic encephalomyelitis/chronic fatigue syndrome: A meta-analysis of public DNA methylation and gene expression data
J. Malato (2021)
10.3390/proteomes9010006
In-Depth Analysis of the Plasma Proteome in ME/CFS Exposes Disrupted Ephrin-Eph and Immune System Signaling
Arnaud Germain (2021)
10.1111/jon.12751
Altered Structural Brain Networks Related to Adrenergic/Muscarinic Receptor Autoantibodies in Chronic Fatigue Syndrome
Hiroyuki Fujii (2020)
10.4236/ape.2020.101007
Validity of 2-Day Cardiopulmonary Exercise Testing in Male Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
C. (Linda) M. C. van Campen (2020)
10.3390/healthcare8030273
Validation of the Severity of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome by Other Measures than History: Activity Bracelet, Cardiopulmonary Exercise Testing and a Validated Activity Questionnaire: SF-36
C. (. van Campen (2020)
10.1371/journal.pone.0236148
Plasma proteomic profiling suggests an association between antigen driven clonal B cell expansion and ME/CFS
Milica Milivojevic (2020)
10.3390/metabo10010034
Comprehensive Circulatory Metabolomics in ME/CFS Reveals Disrupted Metabolism of Acyl Lipids and Steroids
Arnaud Germain (2020)
10.3389/fimmu.2020.582330
Impact of Long-Term Cryopreservation on Blood Immune Cell Markers in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Implications for Biomarker Discovery
E. Gómez-Mora (2020)
10.1007/s12035-020-01939-w
Environmental, Neuro-immune, and Neuro-oxidative Stress Interactions in Chronic Fatigue Syndrome
Geir Bjorklund (2020)
10.1007/978-3-030-16089-0_3
Acupuncture Treatment for Chronic Fatigue Syndrome
Fei Yao (2019)
10.3389/fped.2019.00059
Epstein-Barr Virus Induced Gene-2 Upregulation Identifies a Particular Subtype of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis
J. Kerr (2019)
10.1007/s11011-019-0388-6
Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?
G. Morris (2019)
10.1186/s10020-019-0083-4
Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients
H. Cabanas (2019)
10.3389/fped.2019.00206
Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study
M. Pérez (2019)
10.3390/diagnostics9030080
Pathological Mechanisms Underlying Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Daniel Missailidis (2019)
10.1186/s13643-019-1202-6
A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome
N. Eaton-Fitch (2019)
10.1007/978-3-030-10620-1_9
The Mental Burden of Immunoperception
A. Saghazadeh (2019)
10.3389/fimmu.2019.02545
Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients
Hélène Cabanas (2019)
10.3390/diagnostics9030091
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Comprehensive Review
Mateo Cortes Rivera (2019)
10.1172/JCI132185
Myalgic encephalomyelitis/chronic fatigue syndrome patients exhibit altered T cell metabolism and cytokine associations.
Alexandra H. Mandarano (2019)
10.1186/s12967-019-02155-4
Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients
C. Balinas (2019)
10.1186/s12883-019-1433-0
A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)
M. Corbitt (2019)
10.1186/s40360-018-0203-8
Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation
Natalie Eaton (2018)
10.1080/21641846.2018.1426371
Longitudinal associations of lymphocyte subsets with clinical outcomes in chronic fatigue syndrome
M. Mehalick (2018)
DNA Methylation Modifications Associated with Glucocorticoid Sensitivity and Clinical Subtypes of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
De La Cruz Vega (2018)
10.1080/09553002.2018.1422871
Chronic fatigue and immune deficiency syndrome (CFIDS), cellular metabolism, and ionizing radiation: a review of contemporary scientific literature and suggested directions for future research
A. Rusin (2018)
10.1186/s10020-018-0046-1
Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients
H. Cabanas (2018)
10.3389/fimmu.2018.01028
Association of T and NK Cell Phenotype With the Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
J. L. Rivas (2018)
10.5430/JER.V5N1P1
Incidence rates of brain cancer following an outbreak of Chronic Fatigue Syndrome
C. Lin (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar